117 related articles for article (PubMed ID: 12175892)
1. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.
Knoll J; Miklya I; Knoll B; Yasusa T; Shimazu S; Yoneda F
Life Sci; 2002 Sep; 71(17):1975-84. PubMed ID: 12175892
[TBL] [Abstract][Full Text] [Related]
2. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Knoll J; Yoneda F; Knoll B; Ohde H; Miklya I
Br J Pharmacol; 1999 Dec; 128(8):1723-32. PubMed ID: 10588928
[TBL] [Abstract][Full Text] [Related]
3. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Yoneda F; Moto T; Sakae M; Ohde H; Knoll B; Miklya I; Knoll J
Bioorg Med Chem; 2001 May; 9(5):1197-212. PubMed ID: 11377178
[TBL] [Abstract][Full Text] [Related]
5. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain.
Knoll J; Baghy K; Eckhardt S; Ferdinandy P; Garami M; Harsing LG; Hauser P; Mervai Z; Pocza T; Schaff Z; Schuler D; Miklya I
Life Sci; 2017 Aug; 182():57-64. PubMed ID: 28623006
[TBL] [Abstract][Full Text] [Related]
6. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
[TBL] [Abstract][Full Text] [Related]
7. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).
Knoll J; Miklya I
Life Sci; 2016 Dec; 167():32-38. PubMed ID: 27777099
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, (-)-BPAP.
Knoll J; Miklya I; Knoll B
Life Sci; 2002 Sep; 71(18):2137-44. PubMed ID: 12204771
[TBL] [Abstract][Full Text] [Related]
9. The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
Gaszner P; Miklya I
Neuropsychopharmacol Hung; 2004 Dec; 6(4):210-20. PubMed ID: 15825677
[TBL] [Abstract][Full Text] [Related]
10. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.
Knoll J; Miklya I; Knoll B; Markó R; Kelemen K
Life Sci; 1996; 58(10):817-27. PubMed ID: 8602114
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Miklya I; Knoll J
Life Sci; 2003 May; 72(25):2915-21. PubMed ID: 12697274
[TBL] [Abstract][Full Text] [Related]
12. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release.
Shimazu S; Takahata K; Katsuki H; Tsunekawa H; Tanigawa A; Yoneda F; Knoll J; Akaike A
Eur J Pharmacol; 2001 Jun; 421(3):181-9. PubMed ID: 11516435
[TBL] [Abstract][Full Text] [Related]
13. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Miklya I
Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
[TBL] [Abstract][Full Text] [Related]
14. Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes.
Shimazu S; Tanigawa A; Sato N; Yoneda F; Hayashi K; Knoll J
Life Sci; 2003 May; 72(24):2785-92. PubMed ID: 12679194
[TBL] [Abstract][Full Text] [Related]
15. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
Miklya I
Pharmacol Rep; 2014 Jun; 66(3):453-8. PubMed ID: 24905523
[TBL] [Abstract][Full Text] [Related]
16. Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
Gaszner P; Miklya I
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):5-14. PubMed ID: 16023777
[TBL] [Abstract][Full Text] [Related]
17. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
Shimazu S; Tsunekawa H; Yoneda F; Katsuki H; Akaike A; Janowsky A
Eur J Pharmacol; 2003 Dec; 482(1-3):9-16. PubMed ID: 14659999
[TBL] [Abstract][Full Text] [Related]
18. The fate of (-)1-(benzofuran-2-yl)-2-propylaminopentane . HCl, (-)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain.
Magyar K; Lengyel J; Bolehovszky A; Knoll B; Miklya I; Knoll J
Eur J Drug Metab Pharmacokinet; 2002; 27(3):157-61. PubMed ID: 12365195
[TBL] [Abstract][Full Text] [Related]
19. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Knoll J; Miklya I
Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
[TBL] [Abstract][Full Text] [Related]
20. A tryptamine-derived catecholaminergic enhancer, (-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP], attenuates reinstatement of methamphetamine-seeking behavior in rats.
Hiranita T; Yamamoto T; Nawata Y
Neuroscience; 2010 Jan; 165(2):300-12. PubMed ID: 19883738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
